Figure 5

Overall survival (a) and progression-free survival (b) in estrogen-receptor–negative patients with locally advanced/MBC, by site of lesions at baseline (pooled population). (a) Overall survival was nominally significantly different in estrogen-receptor-negative patients in the overall population, and in patients with bone, lung, lymph node or chest wall/breast/skin metastases at baseline randomized to eribulin compared with TPC/capecitabine. (b) Progression-free survival was nominally significantly different only in estrogen-receptor-negative patients with bone metastases at baseline randomized to eribulin compared with TPC/capecitabine. Control includes TPC and capecitabine; HR values and 2-sided 95% CIs were computed using Cox models with treatment as a covariate and stratified by study, region, prior capecitabine use, and HER2/neu status; nominal P values were based on log-rank tests and stratified as noted above. Medians were based on survival curves adjusted by study. CI, confidence interval; HR, hazard ratio; MBC, metastatic breast cancer; TPC, treatment of physician’s choice.